Carfilzomib experience in relapsed/refractory multiple  myeloma: a single-center experience

Ayşe UYSAL; Nur  Akad SOYER; Melda ÖZKAN; Fahri ŞAHİN; Filiz VURAL; Mahmut TÖBÜ; Murat TOMBULOĞLU; Güray SAYDAM

Article Details

Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience

Authors:

Ayşe UYSAL | Nur Akad SOYER | Melda ÖZKAN | Fahri ŞAHİN | Filiz VURAL | Mahmut TÖBÜ | Murat TOMBULOĞLU | Güray SAYDAM

Publisher:

TUBITAK

Journal:

Turkish Journal of Medical Sciences 2018 Vol.48 Issue 1, pp.80-83

Document Type:

Article

Publication Date:

1/2018

Document Language:

Turkish

Document ID (Org No.):

2000750905

Frequency:

Bimonthly

eISSN:

1303-6165

pISSN:

1300-0144

Abstract:

 

Background/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractory multiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone.  Materials and methods: Twenty-one R/R-MM patients who were treated with CFZ plus dexamethasone between October 2013 and January 2016 were screened. The patients were followed until March 2016 after CFZ treatment.  Results: Ten (47.6%) of the patients were female and 11 (52.4%) of them were male. The median age was 62 (47-76) years. The median number of prior treatment lines was 3 (2-7). The median number of administered cycles of treatment for CFZ was 4 (1-10). The median overall response rate was 26.3%. The most common hematological adverse events were anemia and thrombocytopenia (38%). The most common nonhematological adverse event was fatigue (71.4%). One patient died because of a cerebrovascular event and 1 patient died because of pneumonia during the treatment period. The median duration of response rate and time to next therapy were 8 (7-9) and 3 (2-16) months, respectively. The median overall survival was 8 (0.5-33) months.  Conclusion: Despite the small number of patients, our results suggest that CFZ provides acceptable responses in heavily pretreated R/R-MM patients.

Article Details

Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience

Authors: Ayşe UYSAL | Nur Akad SOYER | Melda ÖZKAN | Fahri ŞAHİN | Filiz VURAL | Mahmut TÖBÜ | Murat TOMBULOĞLU | Güray SAYDAM

Publisher: TUBITAK

Journal: Turkish Journal of Medical Sciences 2018 Vol.48 Issue 1, pp.80-83

Document Type: Article

Publication Date: 1/2018

Document Language: Turkish

Document ID (Org No.): 2000750905

Frequency: Bimonthly

eISSN: 1303-6165

pISSN: 1300-0144

Issues

Authors:

Ayşe UYSAL | Nur Akad SOYER | Melda ÖZKAN | Fahri ŞAHİN | Filiz VURAL | Mahmut TÖBÜ | Murat TOMBULOĞLU | Güray SAYDAM

Publisher:

TUBITAK

Journal:

Turkish Journal of Medical Sciences 2018 Vol.48 Issue 1, pp.80-83

Document Type:

Article

Publication Date:

1/2018

Document Language:

Turkish

Document ID (Org No.):

2000750905

Frequency:

Bimonthly

eISSN:

1303-6165

pISSN:

1300-0144